Common genetic variation in alcohol-related hepatocellular carcinoma: a case-control genome-wide association study
- PMID: 34902334
- DOI: 10.1016/S1470-2045(21)00603-3
Common genetic variation in alcohol-related hepatocellular carcinoma: a case-control genome-wide association study
Abstract
Background: Hepatocellular carcinoma is a frequent consequence of alcohol-related liver disease, with variable incidence among heavy drinkers. We did a genome-wide association study (GWAS) to identify common genetic variants for alcohol-related hepatocellular carcinoma.
Methods: We conducted a two-stage case-control GWAS in a discovery cohort of 2107 unrelated European patients with alcohol-related liver disease aged 20-92 years recruited between Oct 22, 1993, and March 12, 2017. Cases were patients with alcohol-related hepatocellular carcinoma diagnosed by imaging or histology. Controls were patients with alcohol-related liver disease without hepatocellular carcinoma. We used an additive logistic regression model adjusted for the first ten principal components to assess genetic variants associated with alcohol-related hepatocellular carcinoma. We did another analysis with adjustment for age, sex, and liver fibrosis. New candidate associations (p<1 × 10-6) and variants previously associated with alcohol-related hepatocellular carcinoma were evaluated in a validation cohort of 1933 patients with alcohol-related liver disease aged 29-92 years recruited between July 21, 1995, and May 2, 2019. We did a meta-analysis of the two case-control cohorts.
Findings: The discovery cohort included 775 cases and 1332 controls. Of 7 962 325 variants assessed, we identified WNT3A-WNT9A (rs708113; p=1·11 × 10-8) and found support for previously reported regions associated with alcohol-related hepatocellular carcinoma risk at TM6SF2 (rs58542926; p=6·02 × 10-10), PNPLA3 (rs738409; p=9·29 × 10-7), and HSD17B13 (rs72613567; p=2·49 × 10-4). The validation cohort included 874 cases and 1059 controls and three variants were replicated: WNT3A-WNT9A (rs708113; p=1·17 × 10-3), TM6SF2 (rs58542926; p=4·06 × 10-5), and PNPLA3 (rs738409; p=1·17 × 10-4). All three variants reached GWAS significance in the meta-analysis: WNT3A-WNT9A (odds ratio 0·73, 95% CI 0·66-0·81; p=3·93 × 10-10), TM6SF2 (1·77, 1·52-2·07; p=3·84×10-13), PNPLA3 (1·34, 1·22-1·47; p=7·30 × 10-10). Adjustment for clinical covariates yielded similar results. We observed an additive effect of at-risk alleles on alcohol-related hepatocellular carcinoma. WNT3A-WNT9A rs708113 was not associated with liver fibrosis.
Interpretation: WNT3A-WNT9A is a susceptibility locus for alcohol-related hepatocellular carcinoma, suggesting an early role of the Wnt-β-catenin pathway in alcohol-related hepatocellular carcinoma carcinogenesis.
Funding: Ligue Nationale contre le Cancer, Bpifrance, INSERM, AFEF, CARPEM, Labex OncoImmunology, and Agence Nationale de la Recherche.
Copyright © 2022 Elsevier Ltd. All rights reserved.
Conflict of interest statement
Declaration of interests ET received research support from Gilead. NG-C received honoraria from Roche, Gilead, and Ipsen, and support for travel and attending meetings from Gilead. CM received research support from Gilead; consulting fees from Gilead, AbbVie, Novartis, Surrozen, and Julius Clinical; support for travel and attending meetings from Gilead and AbbVie; honoraria from Bayer and Astellas; and acted as a scientific advisor to Gilead and Novartis. J-CN received research support from Bayer and Ipsen. J-PB received consulting fees from Bayer, Roche, and Ipsen; honoraria from Bayer, Ipsen, and Roche; support for travel and attending meetings from Bayer, Ipsen, and Roche; and acted as a scientific advisor to Roche. TG received research support from Gilead, honoraria from AbbVie, and acted as a scientific advisor to GoLiver Therapeutics and Promethera Biosciences. PN received research support from Bristol Myers Squibb, Eisai, and Roche; consulting fees from AstraZeneca, Bayer, Bristol Myers Squibb, Gilead, Eisai, Roche, Ipsen, and Exact Science; honoraria from AstraZeneca, Bayer, Bristol Myers Squibb, Gilead, Eisai, Roche, Ipsen, and Exact Science; support for travel and attending meetings from Ipsen and Roche; and acted as a scientific advisor to AstraZeneca, Bayer, Bristol Myers Squibb, Gilead, Eisai, Roche, Ipsen, and Exact Science. All other authors declare no competing interests.
Comment in
-
Rs708113 in WNT3A-WNT9A and hepatocellular carcinoma risk.Lancet Oncol. 2022 Jan;23(1):14-16. doi: 10.1016/S1470-2045(21)00663-X. Epub 2021 Dec 11. Lancet Oncol. 2022. PMID: 34902337 No abstract available.
-
GWAS reveals variants for alcohol-related hepatocellular carcinoma.Nat Rev Gastroenterol Hepatol. 2022 Feb;19(2):79. doi: 10.1038/s41575-022-00575-0. Nat Rev Gastroenterol Hepatol. 2022. PMID: 35017673 No abstract available.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical